Phaseline

Companies › Pasithea Therapeutics

Pasithea Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PAS-004
MEK 1/2 inhibitor
MAP2K1, MAP2K2Phase 1RAS Mutation; NF1 MutationSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06299839PAS-004Phase 1RAS MutationOncologySep 2027
NCT06961565PAS-004Phase 1NF1 MutationOncologyFeb 2028

From the company's SEC filings

Cash of $46m on 2026-06-30; operating cash outflow about $19m a year; runway about 28 months at that burn, to Nov 2028

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MAP2K1 (1) MAP2K2 (1)

Companies with the same targets

Roche AstraZeneca Pierre Fabre Medicament Shanghai Kechow Pharma Novartis Merck KGaA SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Verastem Pfizer Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.